Cytodyn Inc. (CYDY) Stock Price & Analysis

Cytodyn Inc. (CYDY) fell 4.76% to USD 0.2 as of September 8, 2026 at 13:21 UTC, according to Nexqual real-time market data.

CYDY last closed at USD 0.2; the session ranged USD 0.2–0.21 on volume of 1,581,792 shares. Market capitalization is —, with a 52-week range of USD 0.18–0.4 (OQB). Source: Nexqual, September 8, 2026 at 13:21 UTC.

Key Statistics (as of September 8, 2026 at 13:21 UTC)

Technical Analysis (CYDY)

Nexqual's technical model rates CYDY "SELL" based on 2 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 13:21 UTC.

From Cytodyn Inc.'s Latest SEC 10-K Filing (filed 2026-08-31)

Key Strengths & Strategy (as disclosed to the SEC)

• Natera will also provide customized real-world data (RWD) analyses leveraging its proprietary oncology database, which is the largest multi-timepoint early- and late-stage oncology dataset with more than 2 million plasma timepoints and enriched clinical and imaging records.
• Licensure and Regulation of Biological Products in the United States In the United States, the FDA regulates human drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and in the case of biological products, also under the Public Health Service Act, or the PHSA, and their implementing regulations.
• FDA regulations allow access to investigational drugs under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the drug under a treatment protocol or Treatment IND Application.
• Any product candidate submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as breakthrough therapy designation, priority review and accelerated approval. • Fast Track Designation.

Partnerships

• Pre-Clinical Development of Long-Acting CCR5 Antagonist The Company has an active and ongoing joint development agreement with a third-party company with generative AI drug discovery and development tools in an effort to develop one or more longer-acting molecules.
• On June 4, 2026, Natera, Inc. and CytoDyn jointly announced a strategic collaboration to advance ctDNA-guided development and molecular response analysis in metastatic colorectal cancer.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 13:21 UTC. This page is informational and not investment advice.